Market Overview:
The global diagnostic nuclear medicines market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer and other diseases, growing demand for early diagnosis and treatment, and technological advancements in diagnostic nuclear medicine procedures. The global diagnostic nuclear medicines market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into Tc-99m, F-18, and other types. The Tc-99m segment is expected to account for the largest share of the global diagnostic nuclear medicines market in 2018 owing to its high usage in various applications such as oncology, cardiology, neurology & psychiatry, and others. On the basis of application,the market is divided into oncology (diagnostic & therapeutic), cardiology (diagnostic & therapeutic), neurology & psychiatry (diagnostic), renal imaging (diagnostic), gastrointestinal imaging (diagnostic), obstetrics/gynecology imaging (diagnostic)and others segments which include musculoskeletal Imaging etc.Oncology held a dominant position among all applications due to rising incidencesof cancer across globe .
Product Definition:
Diagnostic nuclear medicines are used to diagnose and treat diseases. They include radioactive tracers that help doctors see how the body is functioning. This information can then be used to determine the best course of treatment.
Tc-99m:
Tc-99m is a radioactive metal ion that is used in medical imaging and therapy. It has wide applications in medical diagnosis such as bone scans, myelography, and single photon emission computerized tomography (SPECT). The growth factor for this market is the increasing demand for SPECT devices to detect tumors which are not visible with the naked eye.
F-18:
F-18 is a radiotracer used in diagnostic nuclear medicines for the diagnosis of diseases such as thyroid, breast cancer, lung cancer and bone metastasis. It is also used to detect the presence of tumor cells in blood or bone marrow. F-18 labeled sugar (18F-sugar) has been approved by the U.
Application Insights:
The other application segment includes neurology, oncology, cardiology and others. Other applications of gamma-emitting radioisotopes include the diagnosis of genetic diseases such as cystic fibrosis and hemoglobin disorders. The other segment dominated the global market in terms of revenue in 2017 due to a high prevalence of cancer across various regions coupled with increasing R&D activities for the development of new diagnostic techniques for oncology related disorders.
For instance, Iodine-131 is used as a tracer throughout PET/CT imaging studies and it has been approved by FDA specifically designed for lung cancer screening purposes only thus driving its demand globally over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure, favorable reimbursement policies, and increasing target diseases are some of the major factors contributing to its growth. In addition, growing R&D investments by government organizations and pharmaceutical companies is expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising medical tourism coupled with improving healthcare infrastructure in emerging countries such as India and China. Moreover, a large number of nuclear medicine procedures are performed in these countries due to low cost compared with developed regions such as North America or Europe; hence it generates high revenue for this region also known as Developed Asia Pacific (DAp).
Growth Factors:
- Increasing incidence of cancer and other diseases that can be diagnosed through nuclear medicine procedures.
- Advances in technology that make nuclear medicine procedures more accurate, efficient, and safe.
- Growing demand for PET scans as a means to diagnose early-stage cancers and other diseases.
- Rising healthcare spending by governments and private insurers to fund nuclear medicine procedures.
- Increasing awareness of the benefits of diagnostic nuclear medicines among physicians and patients alike
Scope Of The Report
Report Attributes
Report Details
Report Title
Diagnostic Nuclear Medicines Market Research Report
By Type
Tc-99m, F-18, Other
By Application
Oncology, Cardiology, Other
By Companies
Bracco Imaging, Bayer, Curium Pharmaceuticals, Nordion, Triad Isotopes, Lantheus, GE Healthcare, China Isotope & Radiation, Jubilant Pharma, Eli Lilly, Novartis, SIEMENS, Dongcheng, Navidea
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Diagnostic Nuclear Medicines Market Report Segments:
The global Diagnostic Nuclear Medicines market is segmented on the basis of:
Types
Tc-99m, F-18, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Cardiology, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bracco Imaging
- Bayer
- Curium Pharmaceuticals
- Nordion
- Triad Isotopes
- Lantheus
- GE Healthcare
- China Isotope & Radiation
- Jubilant Pharma
- Eli Lilly
- Novartis
- SIEMENS
- Dongcheng
- Navidea
Highlights of The Diagnostic Nuclear Medicines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tc-99m
- F-18
- Other
- By Application:
- Oncology
- Cardiology
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diagnostic Nuclear Medicines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diagnostic nuclear medicine is a type of medical imaging that uses radioactive materials to create images of the body. These images can help doctors diagnose and treat diseases.
Some of the major players in the diagnostic nuclear medicines market are Bracco Imaging, Bayer, Curium Pharmaceuticals, Nordion, Triad Isotopes, Lantheus, GE Healthcare, China Isotope & Radiation, Jubilant Pharma, Eli Lilly, Novartis, SIEMENS, Dongcheng, Navidea.
The diagnostic nuclear medicines market is expected to grow at a compound annual growth rate of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diagnostic Nuclear Medicines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Diagnostic Nuclear Medicines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Diagnostic Nuclear Medicines Market - Supply Chain
4.5. Global Diagnostic Nuclear Medicines Market Forecast
4.5.1. Diagnostic Nuclear Medicines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Diagnostic Nuclear Medicines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Diagnostic Nuclear Medicines Market Absolute $ Opportunity
5. Global Diagnostic Nuclear Medicines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Diagnostic Nuclear Medicines Market Size and Volume Forecast by Type
5.3.1. Tc-99m
5.3.2. F-18
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Diagnostic Nuclear Medicines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Diagnostic Nuclear Medicines Market Size and Volume Forecast by Application
6.3.1. Oncology
6.3.2. Cardiology
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Diagnostic Nuclear Medicines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Diagnostic Nuclear Medicines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Diagnostic Nuclear Medicines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Diagnostic Nuclear Medicines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Diagnostic Nuclear Medicines Demand Share Forecast, 2019-2026
9. North America Diagnostic Nuclear Medicines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Diagnostic Nuclear Medicines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Diagnostic Nuclear Medicines Market Size and Volume Forecast by Application
9.4.1. Oncology
9.4.2. Cardiology
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Diagnostic Nuclear Medicines Market Size and Volume Forecast by Type
9.7.1. Tc-99m
9.7.2. F-18
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Diagnostic Nuclear Medicines Demand Share Forecast, 2019-2026
10. Latin America Diagnostic Nuclear Medicines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Diagnostic Nuclear Medicines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Diagnostic Nuclear Medicines Market Size and Volume Forecast by Application
10.4.1. Oncology
10.4.2. Cardiology
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Diagnostic Nuclear Medicines Market Size and Volume Forecast by Type
10.7.1. Tc-99m
10.7.2. F-18
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Diagnostic Nuclear Medicines Demand Share Forecast, 2019-2026
11. Europe Diagnostic Nuclear Medicines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Diagnostic Nuclear Medicines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Diagnostic Nuclear Medicines Market Size and Volume Forecast by Application
11.4.1. Oncology
11.4.2. Cardiology
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Diagnostic Nuclear Medicines Market Size and Volume Forecast by Type
11.7.1. Tc-99m
11.7.2. F-18
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Diagnostic Nuclear Medicines Demand Share, 2019-2026
12. Asia Pacific Diagnostic Nuclear Medicines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Diagnostic Nuclear Medicines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Diagnostic Nuclear Medicines Market Size and Volume Forecast by Application
12.4.1. Oncology
12.4.2. Cardiology
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Diagnostic Nuclear Medicines Market Size and Volume Forecast by Type
12.7.1. Tc-99m
12.7.2. F-18
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Diagnostic Nuclear Medicines Demand Share, 2019-2026
13. Middle East & Africa Diagnostic Nuclear Medicines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Diagnostic Nuclear Medicines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Diagnostic Nuclear Medicines Market Size and Volume Forecast by Application
13.4.1. Oncology
13.4.2. Cardiology
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Diagnostic Nuclear Medicines Market Size and Volume Forecast by Type
13.7.1. Tc-99m
13.7.2. F-18
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Diagnostic Nuclear Medicines Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Diagnostic Nuclear Medicines Market: Market Share Analysis
14.2. Diagnostic Nuclear Medicines Distributors and Customers
14.3. Diagnostic Nuclear Medicines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bracco Imaging
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Curium Pharmaceuticals
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Nordion
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Triad Isotopes
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Lantheus
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GE Healthcare
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. China Isotope & Radiation
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Jubilant Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Eli Lilly
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Novartis
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. SIEMENS
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Dongcheng
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Navidea
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
